Freiburger Sebastian, Caldonazo Tulio, Tasoudis Panagiotis, Färber Gloria, Schulze Paul Christian, Franz Marcus, Doenst Torsten, Kirov Hristo, Diab Mahmoud
Department of Cardiothoracic Surgery, Jena University Hospital-Friedrich Schiller University of Jena, 07747 Jena, Germany.
Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC 27599, USA.
Rev Cardiovasc Med. 2023 May 5;24(5):137. doi: 10.31083/j.rcm2405137. eCollection 2023 May.
Left ventricular assist devices (LVAD) and extracorporeal membrane oxygenation (ECMO) are well established therapies in heart failure (HF) management. Their use is generally associated with a sudden increase in inflammatory mediators, which are often already elevated in patients with HF prior to device implantation. An exaggerated release of proinflammatory cytokines is associated with organ dysfunction and increased mortality. Hemoadsorption has been shown to reduce inflammatory mediators during cardiopulmonary bypass.
To investigate the role of hemoadsorption during the management of acute or chronic heart failure with mechanical circulatory support and its impact on survival.
We systematically searched MEDLINE selecting all studies comparing the use of hemoadsorption during LVAD implantation or veno-arterial (v.a.) ECMO therapy. Records were screened by two different investigators. Reports without a control group and duplicates were excluded.
Our search delivered six studies. One was randomized and five were retrospective studies, of which three were risk-adjusted. During LVAD implantation, one study showed no difference in mortality but higher incidence of respiratory insufficiency in the hemoadsorption group (54% vs 30%, = 0.024) and the other study found higher mortality in the hemoadsorption group (33% vs 0%, = 0.01). During ECMO therapy, three of four studies including the randomized one found no difference in survival or major adverse cardiac events between the hemoadsorption and the control groups. Only one study found lower mortality in the hemoadsorption group (20% vs 60%. = 0.02).
The results of this literature review suggest that the use of hemoadsorption in patients undergoing LVAD implantation might be associated with higher morbidity and mortality. The majority of studies on the use of hemoadsorption during v.a. ECMO therapy showed no effect on mortality or organ dysfunction, while only one small study showed that hemoadsorption was able to reduce mortality. The results are limited by the retrospective nature and the small sample sizes of the majority of the studies included.
左心室辅助装置(LVAD)和体外膜肺氧合(ECMO)是心力衰竭(HF)治疗中已确立的疗法。它们的使用通常与炎症介质的突然增加有关,而这些炎症介质在装置植入前的HF患者中往往已经升高。促炎细胞因子的过度释放与器官功能障碍和死亡率增加有关。血液吸附已被证明可在体外循环期间减少炎症介质。
探讨血液吸附在机械循环支持治疗急性或慢性心力衰竭中的作用及其对生存率的影响。
我们系统检索了MEDLINE,选择了所有比较在LVAD植入或静脉-动脉(v.a.)ECMO治疗期间使用血液吸附的研究。记录由两名不同的研究人员进行筛选。排除无对照组的报告和重复报告。
我们的检索得到六项研究。一项是随机研究,五项是回顾性研究,其中三项进行了风险调整。在LVAD植入期间,一项研究显示血液吸附组的死亡率无差异,但呼吸功能不全的发生率较高(54%对30%,P = 0.024),另一项研究发现血液吸附组的死亡率较高(33%对0%,P = 0.01)。在ECMO治疗期间,包括随机研究在内的四项研究中的三项发现血液吸附组与对照组在生存率或主要不良心脏事件方面无差异。只有一项研究发现血液吸附组的死亡率较低(20%对60%,P = 0.02)。
这篇文献综述的结果表明,在接受LVAD植入的患者中使用血液吸附可能与更高的发病率和死亡率相关。大多数关于在v.a. ECMO治疗期间使用血液吸附的研究显示对死亡率或器官功能障碍无影响,而只有一项小型研究表明血液吸附能够降低死亡率。结果受到大多数纳入研究的回顾性性质和小样本量的限制。